// App-Quantinova.ai

AB0394 (2022) : CLINICAL OUTCOMES UP TO WEEK 48 OF ONGOING FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) LONG-TERM EXTENSION (LTE) TRIAL OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (bDMARD) INADEQUATE RESPONDERS (IR) INITIALLY ON FIL OR PLACEBO IN A PHASE 3 PARENT STUDY (PS)

Researchers

Presenter

  • M. H. Buch

Principal Investigators

  • T. Takeuchi

  • V. Rajendran

  • J. E. Gottenberg

  • A. Pechonkina

  • Y. Tan

  • Q. Gong

  • K. Van Beneden

  • R. Caporali

Medical Centers

  • University of Manchester, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Medicine & Health, Manchester, United Kingdom

  • Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan

  • Galapagos NV, Development, Mechelen, Belgium

  • Strasbourg University Hospital, Department of Hematology, Strasbourg, France

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Galapagos NV, Medical Affairs, Mechelen, Belgium

  • Policlinico S. Matteo, Rheumatology Department, Pavia, Italy

Locations

  • United Kingdom

  • Japan

  • Belgium

  • France

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03025308

  • NCT02873936

Sponsors

  • Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved